aliskiren and ramipril: what the product label says

The product label for ramipril names aliskiren in its drug-interaction information. The complete selected section is reproduced below so that qualifications stay with the finding.

Which products this evidence covers

Ramipril — CAPSULE — ORAL

Labeled active ingredients: RAMIPRIL; RAMIPRILAT. Routes: ORAL. Dosage forms: CAPSULE.

Supporting label passage

Section: 7.3 Other Agents Affecting RAS

In general, avoid combined use of RAS inhibitors. [see Warnings and Precautions (5.7) ] . Do not co-administer aliskiren with ramipril in patients with diabetes [see Contraindications (4) ].

Read the full product label on DailyMed. Label version 2, dated 2026-01-01.

Limits of this evidence

This passage applies to the labeled product and circumstances it describes. It must not be generalized to other routes or formulations. It does not independently validate CDI’s severity category, establish safety for an individual, or replace the full label. The stored interaction description and classification have not been changed by this article.

How this brief was prepared

Automatic checks matched drug identities, retrieved and preserved the label, and checked the full quoted section with AI assistance on 2026-11-02. The public explanation uses a fixed template; model-written medical advice is not published. Independent clinical review has not been recorded.

Discuss your exact medicines with your pharmacist

Ask your pharmacist or prescriber whether the cited products, routes and circumstances apply to your medicines before changing treatment.

Check your medication list with CDI.